RSS

PIM/PI3K inhibitors

Private therapeutics company, Inflection Biosciences, has published preclinical data, demonstrating that its dual mechanism PIM/PI3 kinase inhibitor IBL-202 has promise for the treatment of chronic lymphocytic leukaemia (CLL). more

News

Inflection Biosciences and the RCSI have entered into a research collaboration aiming to understand the mechanisms of resistance to major breast cancer therapies and examine potential new treatment for patients with a cancer that is unresponsive more

News